ASX

EQS-News: EcoGraf HFfree™ Proprietary Purification Achieves 4N 99.99% Carbon

Retrieved on: 
Wednesday, April 10, 2024
Element, Carbon, SPG, ASX, EGR, FMK

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • EcoGraf Limited (ASX: EGR; FSE: FMK; OTCQB: ECGFF) is pleased to provide an update on its HFfree proprietary purification technology for producing active anode material tailored for lithium-ion battery and electric vehicle manufacturers.
  • Purification of an unpurified natural spherical graphite (SPG) has now achieved ‘four nines’ known as 4N purity - 99.99% carbon, which exceeds the standard customer industry requirement of 99.95% carbon for natural spherical graphite
    Table 1 summarises the latest purification results, showing carbon grade and impurity concentrations for major elements from an unpurified SPG with an initial grade of 96.73% carbon.
  • Table 1: Summary of key major elements.

EQS-News: Australian Patent Update

Retrieved on: 
Wednesday, April 10, 2024
Government, Exercise, Federal court, Commissioner, Patent, ASX, United States patent law, Disclosure, EGR, FMK

EcoGraf Limited (“EcoGraf” or the “Company”) (ASX: EGR; FSE: FMK; OTCQB: ECGFF) advises that the delegate of the Australian Commissioner of Patents has issued findings in favour of opposition raised to the Company’s Australian patent application, filed on 1 November 2022 and entitled “Method of Producing Purified Graphite”.

Key Points: 
  • EcoGraf Limited (“EcoGraf” or the “Company”) (ASX: EGR; FSE: FMK; OTCQB: ECGFF) advises that the delegate of the Australian Commissioner of Patents has issued findings in favour of opposition raised to the Company’s Australian patent application, filed on 1 November 2022 and entitled “Method of Producing Purified Graphite”.
  • For full details refer:
    EcoGraf is considering its position in relation to the matter, specifically whether or not it intends to file amendments to overcome the deficiencies identified by the delegate in the Company’s Australian patent application and/or whether to exercise its right of appeal to the Federal Court.
  • The US Patent and Trademark Office has confirmed that the Company’s patent application, filed on 1 November 2022, entitled “Method of Producing Purified Graphite” was granted on 18 July 2023 as US Patent 11,702342 (refer ASX announcement US Patent Granted 19 July 2023).
  • The Company’s EcoGraf HFfree™ Australian Product Qualification Facility is being developed with the support of a $2.9m grant provided by the Australian Government under the Critical Minerals Development Program, with commissioning scheduled to commence next month.

EQS-News: EcoGraf: Product Qualification Facility Commissioning Commenced

Retrieved on: 
Wednesday, April 10, 2024
Facility, Government, PQF, ASX, Mineral, OTCQX, EGR, FMK, Engineering, Commonwealth

EcoGraf Limited (EcoGraf or the Company) (ASX: EGR; FSE: FMK; OTCQX: ECGFF) is pleased to announce an update on construction and commissioning activities for the Product Qualification Facility (‘PQF’ or ‘Facility’) in Western Australia with operations to commence in April 2024.

Key Points: 
  • EcoGraf Limited (EcoGraf or the Company) (ASX: EGR; FSE: FMK; OTCQX: ECGFF) is pleased to announce an update on construction and commissioning activities for the Product Qualification Facility (‘PQF’ or ‘Facility’) in Western Australia with operations to commence in April 2024.
  • The PQF will undertake a number of product campaigns which is scheduled over the remainder of the year, the plant will operate at 5-10kg/hr with the first 5 tonnes of product in place for processing.
  • The Facility will complement the Company’s product testing activities, while the PQF campaigns will benefit from recent flowsheet improvements that is expected to support further reduction in costs while increasing the purity of the material above customers specifications.
  • The Facility is jointly funded through the Commonwealth Government’s A$48.9m Critical Minerals Development Program, which is supporting Australian battery minerals processing capability.

First Phosphate and Groupe Goyette Sign MOU for Logistics Footprint at the Hebertville-Station Intermodal Facility in the Saguenay-Lac-St-Jean Region of Quebec, Canada

Retrieved on: 
Wednesday, March 13, 2024
Lobbying, Government, Indigenous peoples, ASX, Carbon footprint, Transport, Rest, Phosphate, Saint-Hyacinthe, OTC, GG, Rights, Movement, UN, Mining, Rail freight transport

"Our clients in the battery technology industry for electric vehicles ("EVs") and energy storage will be demanding and will require reliable, just-in-time transportation assurances."

Key Points: 
  • "Our clients in the battery technology industry for electric vehicles ("EVs") and energy storage will be demanding and will require reliable, just-in-time transportation assurances."
  • GG is to join the First Phosphate project team and begin to determine the best overall project-based logistics necessary to integrate the Company's product and supply flows with the Hébertville-Station, Quebec intermodal facility.
  • He has practiced law for 15 years and was chief legal advisor on land rights for the Ilnu Nation.
  • He was special advisor/negotiator on the drafting and adoption of the UN General Assembly Declaration on the Rights of Indigenous Peoples.

Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024

Retrieved on: 
Wednesday, April 10, 2024
Organization, Growth, Global health, Public, Research, ASX, RCE, Local government, United, AMR, Ecosystem, Innovate UK, Government, Innovation

Professor Dame Sally Davies, former England Chief Medical Officer, hosting a reception with selected organizations offering Recce strategic partnering opportunities in the AMR space

Key Points: 
  • Professor Dame Sally Davies, former England Chief Medical Officer, hosting a reception with selected organizations offering Recce strategic partnering opportunities in the AMR space
    SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced its selection by the United Kingdom’s (UK) Government Innovation Agency (Innovate UK) to partake in the prestigious UK Antimicrobial Resistance (AMR) Inward Mission 2024.
  • “We are thrilled by the opportunity to collaborate with the UK’s leading AMR experts and institutions and thank the UK government for their support,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • The UK AMR Inward Mission 2024 will host a comprehensive program, including partnering sessions, visits to world-class AMR infrastructure, and interactions with key opinion leaders.
  • The selection of Recce for the UK AMR Inward Mission signifies an important geographic opportunity in its global strategy, particularly in establishing a foothold in the UK’s vibrant AMR research and development ecosystem.

NOVONIX Announces Participation in April Investor Events

Retrieved on: 
Tuesday, April 9, 2024
USN, RET, Admiral, AGM, ASX, AEST, EDT, NVX

BRISBANE, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX”), a leading battery materials and technology company, today announced that members of the executive team are scheduled to participate in the following upcoming investor events in April 2024:

Key Points: 
  • BRISBANE, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX”), a leading battery materials and technology company, today announced that members of the executive team are scheduled to participate in the following upcoming investor events in April 2024:
    NOVONIX’s Annual General Meeting will be held in Brisbane, Australia on April 17th, details for participation can be found at the designated AGM webpage ;
    Dr. Chris Burns, CEO of NOVONIX, will provide prepared remarks in a business update webcast for the quarter-ended March 31st, 2024.
  • The webcast link and presentation materials will be available Wednesday, April 17th at 8:30 am AEST or Tuesday, April 16th at 6:30 pm EDT;
    Maxim Group is hosting their International Mining Collaboration: The World Needs More Mining & Processing virtual conference on April 23rd with NOVONIX participating at 11:30 am EDT; and
    Janney Montgomery Scott Virtual CEO Fireside Chat, April 24th at 1:00 pm EDT.
  • This announcement has been authorized for release by NOVONIX Chairman, Admiral Robert J. Natter, USN Ret.

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, April 9, 2024
HER2, CD8, Phosphorylation, Survival, Cholangiocarcinoma, Immunotherapy, RECIST, Oncology, MAST, Patient, City, Degranulation, ASX, ADCC, Cancer, Hope, Overalls, Pembrolizumab, PRS, AACR, SPECT, Vaccination, Melanoma, Recurrence, PD-L1, IMU, Medical imaging

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.

Key Points: 
  • Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.
  • SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIRE) -- Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.
  • HER-Vaxx induced HER2-specific antibodies able to mediate antibody-dependent cell cytotoxicity (ADCC) and inhibit intracellular HER2 phosphorylation and correlated with tumour reduction.
  • The HER-Vaxx induced HER2-specific antibodies demonstrate a similar mechanism of action to HERCEPTINâ validating B cell immunotherapy as an alternative anti-cancer agent to monoclonal antibodies.

Osisko Announces Q1 2024 Geo Deliveries and Select Asset Updates

Retrieved on: 
Monday, April 8, 2024
Odyssey, Mining, Copper, Australian Securities Exchange, Osisko Gold Royalties, Silver, SSRP, GEOS, SAG, Gold, Senate, Annual report, Corporation, ASX, Acquisition, Mineral, Refused, CSA, Abitibi, Agnico Eagle, Ventilation, NSR, Resource

In addition, Osisko is excited to provide some select asset updates.

Key Points: 
  • In addition, Osisko is excited to provide some select asset updates.
  • Osisko earned 22,259 attributable gold equivalent ounces1 (“GEOs”) in the first quarter of 2024.
  • Osisko owns a 2% NSR royalty on the Ermitaño project and the Cumobabi property, including the Luna and Soledad Zones.
  • Osisko provides notice of the first quarter 2024 results and conference and webcast call details.

EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk”

Retrieved on: 
Monday, April 8, 2024
Community, Genomics, Health, Genetic testing, GTG, Partnership, Knowledge, ASX, Security (finance), Risk, Krystal Barter, Woman, Risk assessment, Heart, Movement, BRCA1, Writing, Nursing

"Know Your Risk" is a movement towards empowering every woman with the knowledge to take charge of her health.

Key Points: 
  • "Know Your Risk" is a movement towards empowering every woman with the knowledge to take charge of her health.
  • Community Support: Be part of the launch of a "Know Your Risk" campaign, fostering a supportive community focused on empowering women to make informed decisions about their health.
  • Together with Humanise Health, a leading patient advocacy agency, we are at the forefront of advocating for preventative health and personalized health strategies.
  • This partnership for the "Know Your Risk" event underscores our collective dedication to empowering women with the knowledge to proactively manage their health.

Perseus's Offer for OreCorp Unconditional and Best and Final

Retrieved on: 
Monday, April 8, 2024
PRU, ASX, Perseus, Business, Corporations Act 2001, Chapter Six, Management

OreCorp Shareholders should Accept the Offer now in respect of Your OreCorp Shares.

Key Points: 
  • OreCorp Shareholders should Accept the Offer now in respect of Your OreCorp Shares.
  • Perseus refers to OreCorp’s announcement today noting that OreCorp is actively working with Perseus to transition the OreCorp Board and management team.
  • Perseus Chairman and Chief Executive Officer, Jeff Quartermaine, said:
    “We are pleased with the positive response from OreCorp Shareholders and to be able to declare the Offer unconditional and best and final.
  • The Offer provides compelling benefits and value to OreCorp Shareholders, as well as the opportunity for OreCorp Shareholders to realise certain and expedited value for their OreCorp Shareholdings.